Medtronic PLC $MDT Shares Sold by Syntax Research Inc.

Syntax Research Inc. trimmed its holdings in Medtronic PLC (NYSE:MDT) by 87.5% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 803 shares of the medical technology company’s stock after selling 5,637 shares during the quarter. Syntax Research Inc.’s holdings in Medtronic were worth $63,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Monetary Solutions Ltd bought a new stake in Medtronic during the 4th quarter valued at $27,000. Anfield Capital Management LLC grew its stake in shares of Medtronic by 410.7% in the fourth quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock worth $27,000 after purchasing an additional 230 shares in the last quarter. Acumen Wealth Advisors LLC bought a new position in shares of Medtronic in the fourth quarter worth $29,000. Imprint Wealth LLC acquired a new position in shares of Medtronic during the third quarter valued at $31,000. Finally, Basepoint Wealth LLC acquired a new position in shares of Medtronic during the fourth quarter valued at $32,000. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Medtronic Stock Up 0.7%

MDT opened at $92.87 on Friday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 1.62 and a current ratio of 2.13. The company has a market capitalization of $118.87 billion, a PE ratio of 22.87, a P/E/G ratio of 2.16 and a beta of 0.56. The stock’s fifty day moving average is $86.52 and its 200-day moving average is $85.31. Medtronic PLC has a one year low of $73.31 and a one year high of $106.33.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share for the quarter, beating the consensus estimate of $1.39 by $0.06. The business had revenue of $9.76 billion during the quarter, compared to analysts’ expectations of $9.55 billion. Medtronic had a return on equity of 14.89% and a net margin of 13.93%.The company’s quarterly revenue was up 13.7% on a year-over-year basis. During the same quarter last year, the business posted $1.26 earnings per share. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, equities analysts predict that Medtronic PLC will post 5.95 EPS for the current fiscal year.

Medtronic Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 16th. Stockholders of record on Friday, September 25th will be given a dividend of $0.72 per share. The ex-dividend date is Friday, September 25th. This represents a $2.88 annualized dividend and a dividend yield of 3.1%. Medtronic’s dividend payout ratio (DPR) is 70.94%.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on MDT. Bank of America upped their price objective on shares of Medtronic from $95.00 to $110.00 and gave the stock a “buy” rating in a report on Wednesday. Mizuho set a $115.00 target price on shares of Medtronic in a research note on Wednesday. JPMorgan Chase & Co. lowered their target price on shares of Medtronic from $100.00 to $86.00 and set a “neutral” rating on the stock in a research note on Thursday, June 4th. Wells Fargo & Company boosted their price target on shares of Medtronic from $102.00 to $104.00 and gave the stock an “overweight” rating in a research report on Wednesday. Finally, TD Cowen upped their price target on shares of Medtronic from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Friday, August 28th. Nineteen research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $103.92.

Insider Activity

In other news, EVP Harry Kiil sold 4,189 shares of Medtronic stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $80.44, for a total value of $336,963.16. Following the transaction, the executive vice president owned 37,227 shares of the company’s stock, valued at $2,994,539.88. The trade was a 10.11% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 0.27% of the stock is owned by corporate insiders.

Medtronic News Roundup

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic’s fiscal first-quarter results exceeded expectations, with adjusted EPS of $1.45 versus the $1.39 consensus and revenue of $9.76 billion versus $9.55 billion expected. Revenue increased 13.7% year over year, while management raised its fiscal 2027 outlook to approximately $5.94-$6.00 in EPS. Medtronic Begins Fiscal 2027 With a Beat-and-Raise
• Positive Sentiment: Analysts responded favorably to the earnings beat and raised guidance. RBC reaffirmed its Outperform rating with a $118 price target, while TD Cowen maintained a Buy rating; other firms also increased their targets. Medtronic Analysts Raise Their Forecasts
• Positive Sentiment: Management highlighted broad-based growth across major franchises and newer platforms, including robotics and ablation. Investors view this as evidence that Medtronic’s multiyear growth recovery may be gaining momentum. MDT Earnings Call Focuses on Broad Growth
• Positive Sentiment: A PERSIST addendum study is generating additional real-world evidence for Medtronic’s Inceptiv spinal cord stimulation system, potentially strengthening physician adoption and investor confidence. Medtronic’s PERSIST Study
• Positive Sentiment: Medtronic entered a strategic partnership with Cornerstone Robotics intended to expand global access to robot-assisted surgery, supporting its long-term robotics strategy. Cornerstone Robotics Partnership
• Negative Sentiment: Market strategists warned that Medtronic has become a crowded healthcare-sector trade. The recommendation included using options to bet on a decline, reflecting concern that excessive bullish positioning could limit further gains or trigger a pullback. Crowded Healthcare Stocks

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).